pegylated IL-2 8MW2311
Term · Oncology and biomedicine · MLC-T-ONC-015923
A polyethylene glycol (PEG)-conjugated form of the cytokine interleukin-2 (IL-2), with potential immunopotentiating and antineoplastic activities. Upon administration, pegylated IL-2 8MW2311 activates the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway. This induces the proliferation of CD8+ T cells, enhances tumor cell killing and decreases tumor cell proliferation. Pegylation of IL-2 protects the cytokine from degradation.
| Identifier | MLC-T-ONC-015923 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | pegylated interleukin-2 8MW2311; PEG-conjugated IL-2 8MW2311 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015923",
"term": "pegylated IL-2 8MW2311",
"field": "Oncology and biomedicine",
"definition": "A polyethylene glycol (PEG)-conjugated form of the cytokine interleukin-2 (IL-2), with potential immunopotentiating and antineoplastic activities. Upon administration, pegylated IL-2 8MW2311 activates the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway. This induces the proliferation of CD8+ T cells, enhances tumor cell killing and decreases tumor cell proliferation. Pegylation of IL-2 protects the cytokine from degradation.",
"synonyms": [
"pegylated interleukin-2 8MW2311",
"PEG-conjugated IL-2 8MW2311"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/pegylated-il-2-8mw2311/"
}
Record 12,868 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.